The definitive forensic engine for quantifying Non-Hodgkin Lymphoma (NHL) damages, calibrated against the $10.9B global settlement funds.
$10.9B
Consolidated Fund
165,000+
Active Claims
MDL 2741
Target MDL
Level 4
Discovery Status
The 2026 U.S. Supreme Court review of the Durnell case represents a critical shift in Roundup liability. Our engine accounts for the 'Failure to Warn' preemption risks and how they impact Bayer's global reserve allocations for new cancer filings.
Evaluating IARC Group 2A carcinogen benchmarks and biological causality markers for Tier 1 ranking.
Analyzing chromosome damage and oxidative stress markers linked to glyphosate phosphonate exposure.
Tapping into discovery evidence revealing suppressed internal studies on NHL causality.
Differentiation between DLBCL, Follicular, and SLL/CLL in the 2026 point-score matrix.
Average settlements range from $50,000 to $250,000, but Tier 1 cases with significant medical multipliers reach $1M+.
The Group 2A 'Probable Carcinogen' status anchored the biological plausibility required for federal and state-level expert testimony.
It may limit future 'Failure to Warn' claims in some jurisdictions, but over 60,000 active cases are already consolidated under discovery patterns that bypass these preemptions.